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Abstract
Background: Current conventional vaccination approaches do not induce potent CD8 T-cell responses for fighting mostly
variable viral diseases such as influenza, avian influenza viruses or HIV. Following our recent study on vaccine penetration by
targeting of vaccine to human hair follicular ducts surrounded by Langerhans cells, we tested in the first randomized Phase-
Ia trial based on hair follicle penetration (namely transcutaneous route) the induction of virus-specific CD8 T cell responses.
Methods and Findings: We chose the inactivated influenza vaccine – a conventional licensed tetanus/influenza
(TETAGRIPH) vaccine – to compare the safety and immunogenicity of transcutaneous (TC) versus IM immunization in two
randomized controlled, multi-center Phase I trials including 24 healthy-volunteers and 12 HIV-infected patients. Vaccination
was performed by application of inactivated influenza vaccine according to a standard protocol allowing the opening of the
hair duct for the TC route or needle-injection for the IM route. We demonstrated that the safety of the two routes was
similar. We showed the superiority of TC application, but not the IM route, to induce a significant increase in influenza-
specific CD8 cytokine-producing cells in healthy-volunteers and in HIV-infected patients. However, these routes did not
differ significantly for the induction of influenza-specific CD4 responses, and neutralizing antibodies were induced only by
the IM route. The CD8 cell response is thus the major immune response observed after TC vaccination.
Conclusions: This Phase Ia clinical trial (Manon05) testing an anti-influenza vaccine demonstrated that vaccines designed for
antibody induction by the IM route, generate vaccine-specific CD8 T cells when administered transcutaneously. These
results underline the necessity of adapting vaccination strategies to control complex infectious diseases when CD8 cellular
responses are crucial. Our work opens up a key area for the development of preventive and therapeutic vaccines for
diseases in which CD8 cells play a crucial role.
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Introduction
Inducing CD8 T cell-mediated protective responses would be
beneficial in eliminating infected cells and limiting virus or cancer
dissemination. Classical preventive vaccines, however, except for
live viral vectors and multiple DNA immunizations, are designed
to generate neutralizing antibodies. The use of live attenuated
vaccines known to induce strong CD8 T cell responses is limited
by the risk of uncontrolled virus dissemination in immunocom-
promised individuals (e.g., with HIV or elderly) as well as by vector
or pathogen-specific pre-existing immunity that limits the efficacy
of vaccine administration or readministration [1–4]. The devel-
opment of successful vaccines against HIV, malaria, tuberculosis,
and cancers will require efficient, potent, and durable T cell
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responses [5–8]. In some cases involving high virus variability, the
cross-reactivity of CD8 responses may be beneficial for recall
responses [7,9]. Although there is still no clear definition of the
quality of effector T cells required for protection, it is commonly
accepted that one of its fundamental characteristics is the
magnitude and the nature of T cell responses [10]. Recently,
benchmarks were determined for primary CD8+ T cell responses
in humans induced by two of the most effective vaccines ever
developed, those against yellow fever and smallpox [11]. The
importance of these responses has been shown in many viral
diseases and cancers, in both mouse and human models [12–15],
and their persistence has been observed in the absence of
circulating antigens [16–19]. The generation of such immune
cells is thus of crucial interest in studying long-term immune
responses to pathogens and in vaccine development.
Recent advances in understanding the central role of antigen-
presenting cells (APCs) in the skin have prompted numerous
studies of this organ as an immunization route [20–23]. It has been
suggested that differential targeting of epidermal or dermal APCs
might also produce differential immune responses [21,23]. The
main routes of immunization in humans – the muscle and the
subcutaneous layer – are low in dendritic cells (DCs), and vaccines
injected by these routes generally require adjuvant to augment DC
recruitment and activation and to improve their immunogenicity
[24]. Moreover, recent reports of the involvement of epithelial
DCs in CD8 cell cross-priming suggests that vaccination via the
cutaneous route may help to induce cellular immune responses
[25–27]. Numerous concepts for vaccine delivery to the skin have
thus been developed, but have not yet met expectations.
Hence, strong evidence indicates that targeting vaccine to the
skin should effectively induce cellular immune responses [24,28].
Glenn and collaborators elegantly demonstrated the efficacy of
transcutaneous (TC) immunization in inducing humoral immune
responses in humans [25,29–34]. Frerichs et al [35] recently
introduced a skin preparation system for improved TC vaccine
delivery based on skin surface abrasion with silicone carbide
particles, eliciting humoral responses. However, the induction of T
cell immune responses, so well documented in murine models after
TC immunization, remains to be shown in human.
We previously demonstrated that penetration of topically
applied nanoparticles increased after application of cyanoacrylate
skin surface stripping (CSSS) to human skin explants: the particles
entered epidermal Langerhans cells (LCs), possibly via hair follicles
[36]. We recently proposed that the cellular responses we observed
to vaccine compounds were induced by the vaccine’s penetration
through hair follicular ducts, which are surrounded by APCs (LCs
and DCs) [36,37]. In contrast to the interfollicular epidermis, the
hair follicle infundibulum must be considered highly permeable,
and skin DCs, including epidermal LCs, all residing in and around
the hair follicles, may thus be highly accessible to topically applied
vaccines [38]. In a first pilot study by our groups, we targeted an
inactivated influenza vaccine at the hair follicles, with a protocol
that used only a single CSSS procedure before the vaccine
application. We found that TC vaccination after one CSSS
procedure was safe and, most interestingly, effective in inducing
cellular immune responses [37].
Questions nonetheless remain about how best to shape the
nature and quality of human immune responses to vaccines. In
particular, we wondered whether the site of antigen delivery would
affect the nature and the quality of the immune response and
whether this method of targeting the skin’s APCs would be capable
of inducing CD8 T cell responses to a conventional inactivated
influenza vaccine designed to induce vaccine-specific antibodies.
We thus conducted two randomized controlled phase I clinical
trials simultaneously in two groups of healthy individuals and a
group of HIV-infected patients. Because this strategy can be of
major help for HIV vaccination, we proposed to include HIV
patients in parallel to healthy subjects, for safety and immunoge-
nicity of this new method of vaccination. The transcutaneous
vaccination protocol used is based on a single CSSS procedure that
allows the opening of the hair follicular duct prior to application of
a combined tetanus and influenza (TETAGRIPH) vaccine,
compared with the conventional intramuscular (IM) immunization.
The safety of the TC vaccine application was confirmed. More
importantly, we demonstrated for the first time that TC
application of an influenza vaccine induced a significant increase
in influenza-specific CD8 responses compared with the IM route.
The effects of this application on the intensity and quality of the
influenza–specific effector T cells were studied in detail.
Results
Safety of TC compared with IM vaccination by
inactivated influenza/tetanus vaccine in healthy
volunteers and HIV-infected patients
In this randomized, investigator-blinded comparative Phase I
study, we first evaluated the safety of TC compared to IM
administration of a licensed non-adjuvanted tetanus+inactivated
influenza vaccine (TETAGRIPH) in healthy volunteers (cohort I)
and in HIV-infected patients (cohort II). All 24 healthy individuals
completed the study protocol (12 in each group). The HIV-
infected cohort was terminated early due to the onset of influenza
season, and only 14 patients completed the study protocol: 6 in the
TC group and 8 in the IM group. Table 1 summarizes the
demographic and baseline characteristics of each group.
The primary safety endpoint was clinical local and systemic
tolerance to vaccine administration by each route. Safety analyses
of all 24 healthy volunteers and all 14 chronically HIV-infected
patients who completed the study showed that the TC mode of
administration was well tolerated in both populations (Table 2). All
reactions and adverse events during the follow-up period (D1 to
D28) were recorded. No serious adverse events were reported in
the 28 days after TETAGRIPH administration in any recipient –
healthy volunteer or HIV+ patient, TC or IM administration.
Moderate local reactions occurred in 3 TC vaccinated healthy
individuals (erythema at D1 in one volunteer and erythema at D3
in another one, erythema and swelling in a third volunteer). Mild
local reactions occurred in IM vaccinated subjects. Three
moderate systemic reactions were recorded for cohort I subjects,
as described for both IM and TC groups in Table 2. Axillary
adenopathy occurred in one TC vaccinated subject at D7 and D14
(Table subjects 2).
There was no significant increase in local adverse events,
including erythema, itching, pain, swelling, and axillary node
enlargement, or in the incidence of systemic (grade $3) adverse
events (e.g., fever, myalgia, and diarrhea) in either cohort after TC
compared to IM administration.
In Cohort II composed of HIV-infected individuals, moderate
local reactions occurred in 6 TC vaccinated subjects. Two
moderate systemic reactions were recorded for cohort II subjects,
which are all detailed in Table 2.
Overall, the tolerance of the investigational TC route of vaccine
administration was good.
Defect in induction of influenza-specific neutralizing Ab
responses by the TC but not by IM vaccination route
Influenza vaccines are designed to induce neutralizing antibody
(NAb) responses after IM or subcutaneous (SC) administration in
Transcutaneous Vaccination
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humans. NAb responses are therefore the reference criteria for
evaluating the efficacy of influenza and tetanus vaccines. NAb
responses were evaluated by an independent National Influenza
reference center. Serum samples from D0 to D28 were
simultaneously tested for strain-specific inhibition of HAI after
TETAGRIPH administration by both routes to the 24 healthy
subjects (Table 3) and the 14 HIV+ patients (Table 4).
Results are reported for the geometric mean titers (GMT) of the
A/CALIFORNIA/7/2004 H3N3 and A/NEW CALEDONIA/
20/99 H1N1 strains at D14 and D28 in healthy volunteers
Table 1. Demographic and Baseline Characteristics.
Cohort I TC vaccination IM vaccination
Healthy Volunteers n median [range] Q1–Q3 n median [range] Q1–Q3
Age 12 31 [22–40] 25–37 12 28 [18–40] 24–32
BMI* 12 22 [21–25] 21–23 12 22 [21–24] 21–23
Phototype II 8 8
phototype III 4 4
Phototype IV
Cohort I TC vaccination IM vaccination
HIV+ volunteers n median [range] Q1–Q3 n median [range] Q1–Q3
Age 6 31[31–44] 33–44 8 40 [32–45] 37–45
BMI* 6 22 [21–26] 21–25 8 24 [21–25] 21–25
CD4 T cells
Nadir (cells/ml) 6 308 [265–436] 274–365 8 266 [203–440] 226–347
baseline (cells/ml) 6 1022 [623–1257] 623–1257 8 724 [544–1082] 577–834
Baseline (%) 6 42 [35–51] 35–51 8 31 [20–40] 27–40
Vial Load (copies/ml) 6 ,400 8 ,400
Phototype II 2 6
phototype III 4 2
Phototype IV
*BMI Body mass Index.
doi:10.1371/journal.pone.0010818.t001
Table 2. Summary of clinical safety.
Cohort I - Healthy Volunteers Cohort II - HIV+ volunteers
n 12 12 24 12 12 24
Severity TC IM Total TC IM Total
Local reactions None 2 7 10 0 5 7
(p = 0.05) Mild 7 5 11 0 3 5
Moderate 3 0 3* 6 0 6#
Severe 0 0 0 0 0 0
Systemic events None 6 4 10 3 3 6
(p = 0.07) Mild 4 7 11 2 4 6
Moderate 2 1 3** 1 1 2##
Severe 0 0 0 0 0 0
Statistical significance was set at p,0.05.
*Moderate local reactions occurred in 3 TC vaccinated healthy individuals and included erythema at D1 in one volunteer and erythema at D3 in another one. The third
volunteer experienced erythema and swelling at D1 and erythema at D3. No local reactions occurred in IM vaccinated subjects.
**Three moderate systemic reactions were recorded for cohort I subjects. The subject receiving IM vaccination experienced pain while breathing after sport accident on
D7 and D14. Only volunteer experienced vomiting at D28 after TC vaccination. Axillary adenopathy occurred in one TC vaccinated subject at D7 and D14 and was the
only systemic event, which was considered as related to the mode of administration by the investigator.
#Moderate local reactions occurred in 6 TC vaccinated HIV-infected individuals and included erythema at D3 in one volunteer, erythema at D14 in another volunteer as
well as itching at D1 and D3 in two subjects. One volunteer experienced Itching at D1 followed by erythema at D3, D7, D14 and D21. One erythema and desquamation
in D14, D21 and D28. No local reactions occurred in IM vaccinated subjects.
##Two moderate systemic reactions were recorded for cohort II subjects. Only volunteer reported an upper respiratory tract infection at D28 after IM vaccination. One
TC vaccinated individual experienced malaise and myalgia at D1 after vaccination.
doi:10.1371/journal.pone.0010818.t002
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(Cohort I, Table 3). There were no significant differences at
baseline for antibody titers between the two study arms. IM
vaccination induced the expected influenza-specific NAb responses
to hemagglutinin with 75% seroprotection and seroconversion
rates together with a significant increase in the antibody titers at
D14, while TC vaccination did not. Indeed, TC vaccination did
not induce any detectable influenza-specific NAb responses.
There were no significant differences at baseline for antibody
titers between the two study arms in HIV-infected individuals and
we found similar results among the cohort of HIV-infected
volunteers with the absence of NAb responses in the TC group
compared to IM group (Cohort II, Table 4).
Similar differences between the TC and IM groups were
observed for the induction of NAb responses against tetanus toxin,
as reported in supplemental Table S1. The two study arms (TC
versus IM) thus differed significantly for all the NAb parameters
we measured.
Thus, we found a striking absence of humoral responses to TC
compared with IM vaccination.
Selective amplification of CD8 T cell responses after TC
compared with IM vaccination in healthy individuals
The epidermal route of immunization described in our study is
intended to target mostly epidermal LCs [36]. These APCs have
been shown to be more potent in inducing CD8 cells in in vitro
studies [20–23]. In addition, effector CD4 and CD8 cells both
provide cellular immune responses and can secrete multiple
cytokines that reflect the quality of the effector-cell compartment
of the immune responses. Multiparametric flow cytometry assays
were performed to determine the relative importance of the
subpopulations of influenza-specific CD3+CD4+ and CD3+CD8+
T cells that produce IL-2, IFN-c, and TNF-a. Overlapping
peptides were designed for three major influenza antigens included
in the seasonal vaccine: i) H3, a recent strain not contained in
seasonal influenza vaccines in Europe over the past five years, ii)
H1, repeatedly present in influenza seasonal vaccines over the past
five years, and iii) NP. We further analyzed IL-2, IFN-c, and TNF-
a production by CD4 and CD8 cells after ex vivo stimulation of T
cells with overlapping 20-mer peptides of H3, H1, and NP. Because
of the high variability of baseline influenza-specific T cells in
healthy individuals, we measured the course of influenza-specific T
cell responses from D0. Strikingly, we found that the frequencies of
H3-, H1-, and NP-specific CD8 cells producing cytokines (IL-2,
IFN-c, and TNF-a) were significantly higher after TC than after
IM vaccination (H3 p=0.0164, H1 p=0.031, NP p= 0.007),
mainly because the levels of CD8 responses after IM administration
was extremely low (Figure 1, upper panels). Influenza-specific CD4
responses were similar for both routes (H3 p=0.719, H1 p= 0.408,
NP p= 0.299). In addition, we found a higher proportion of positive
Table 3. Anti-influenza specific neutralizing antibodies in healthy individuals.
A/NEW CALEDONIA A/CALIFORNIA
TC IM p value TC IM p value
Prior vaccination – Day 0
GMT 15.5 23.1 0.31 20 36.8 0.14
Seroconversion rate 2/12 (17%) 4/12 (33%) 0,64 3/13 (25%) 8/12 (67%) 0.10
Post vaccination - Day 28
GMT 15.5 123.8 ,0.001 20 208.2 0.001
Mean GMT increase .2.5 1.0 5.36 ,0.001 1.0 5.66 0.003
Seroconversion rate .70% 2/12 (17%) 10/12 (83%) 0.003 3/12 (25%) 9/12 (75%) 0.003
Seroconversion rate 0/8 (0%) 5/7 (71%) 0.007 0.6 (0%) 1/4 (25%) 0.40
Significant increase in Ab titers 0/4 (0%) 3/5 (60%) 0.017 0/6 (0%) 6/8 (75%) 0.01
Seroconversion rate or significant Increase in Ab titers 0/12 (0%) 8/12 (67%) 0.001 0/12 (0%) 7/12 (58%) 0.005
Statistical significance was set at p,.05.
doi:10.1371/journal.pone.0010818.t003
Table 4. Anti-influenza specific neutralizing antibodies in HIV-infected individuals.
A/NEW CALEDONIA A/CALIFORNIA
TC IM p value TC IM p value
Prior vaccination – Day 0
GMT 13.4 10.1 ns 29.0 19.2 ns
Seroconversion rate 0/6 (0%) 0/8 (0%) ns 3/6 (50%) 3/8 (38%) ns
Post vaccination - Day 28
GMT 14.0 49.6 ,0.001 26.8 129.1 ,0.001
Mean GMT increase .2.5 1.0 4.9 ,0.001 0.9 6.7 0.003
Seroconversion rate .70% 1/6 (17%) 5/8 (63%) 0.005 2/6 (33%) 6/8 (75%) 0.005
Statistical significance was set at p,0.05.
doi:10.1371/journal.pone.0010818.t004
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responders after TC compared with IM immunization, as depicted
in Figure 1 (upper panels) (x2 test, H3 p= 0.02, H1 p=0.035, NP
p=0.035) for influenza-specific CD8 but not CD4 responses (Fig 2,
lower panels). Note the very high frequencies of CD8+cytokine+
cells against H3 proteins after TC vaccination. Overall, we
observed preferential induction of CD8 responses against all three
protein compounds included in the inactivated influenza vaccine
when administered by the TC but not the IM route.
Representative flow cytometric analyses are shown for H3-
specific CD3+CD8+ and H3-specific CD3+CD4+ cells by each
vaccination route (Figure 2A, 2B). Besides the absence of any
increase in influenza-specific CD8 cells after IM vaccination, we
also observed significant differences in the distribution of single
(SP), double (DP) and triple (TP) cytokine producing CD4 cells on
D28 according to the vaccination route. Pie chart analyses
summarize the differential distribution of influenza-specific CD4
cells and underline the impact of vaccination route on the quality
of vaccine-specific effector T cells (Figure 2C and 2D).
In addition, a tetanus-specific cellular response was tested by
IFN-c-ELISPOT assays, as shown in supplemental Figure S1.
Because the cellular response level was below the detection level of
the ELISPOT assay, we did not perform further analysis of the
quality of the tetanus-specific T cell responses.
Finally, we analyzed the quality of cellular immune responses in
HIV+ volunteers (cohort II) after ex vivo stimulation of peripheral
blood cells with the same overlapping peptides covering H3
(Figure 3), H1, and NP (data not shown). Intracellular cytokine
staining assays were performed to assess the production of IL-2,
IFN-c, and TNF-a in CD4 and CD8 cells. We found that H3-
specific CD8 cells tended to be slightly more frequent after TC
than after IM vaccination in these volunteers (p = 0.09 at day 14
and p= 0.2 at day 28) (Figure 3). This was not the case for H3-
specific CD4 responses (p = 0.59), although the small number of
individuals tested made it very difficult to obtain significant results
(Figure 3). Similar results were observed for H1 and NP proteins
(data not shown). Note that the number of HIV+ volunteers able
Figure 1. Differential induction of CD4 and CD8 T cell responses after TC vaccine application compared to IM immunization in
healthy individuals. Intracytoplasmic cytokine staining (ICS) of influenza-specific effector CD4 and CD8 responses was performed on frozen PBMC
samples from vaccinated individuals: 10/12 from the TC group and 7–9/12 from IM group with 90% cell viability after thawing. Three million cells
were stimulated with the overlapping peptide covering H3, H1, and NP for 12 hours at 37uC. Brefeldin A was added 4 h before harvesting. ICS was
performed by flow-cytometric assays on CD3+CD4+ (left panels) and CD3+CD8+ T cells (Right panels). At least 1,000,000 live events according to
forward and side scatter parameters were accumulated and analyzed (M&M section). The expression of IFN-c, TNF-a, and/or IL-2 (triple+double+single
cytokine positive cells) by influenza-specific T cells was analyzed with the Boolean gating function of FlowJo software. Results are shown as
percentages of cytokine-producing T cells (D Day 28- Day 0) after subtracting the unstimulated cell background. Mann-Whitney test was used to
compare continuous variables between the groups. Significance was set at p,0.05. Responders are determined when (D Day 28-Day 0) were.0. The
x2 test was used to define categorical variables between TC and IM groups.
doi:10.1371/journal.pone.0010818.g001
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to be tested was reduced because of the short period available until
the flu season.
These observations suggest that the effect of the TC route on
preferential amplification of vaccine-specific CD8 cells in HIV+
individuals was similar to that in healthy individuals. They need,
however, to be confirmed in a larger sample of such subjects.
Overall, this result demonstrates for the first time that the route of
immunization affects the quality of immune responses and in
particular the quality of T cells.
Discussion
We showed that hair follicular targeting of an inactivated
influenza vaccine by the trancutaneous route induced preferen-
tially CD8 effector T cells rather than humoral immune responses
when compared to a conventional IM route, in a randomized,
controlled Phase I clinical trial in healthy volunteers. Our work is
the first demonstration that the immunization route in humans
affects the magnitude and quality of CD8 T cell responses as well
as the intrinsic quality of cytokine-producing CD4 effector cells
after TC and IM vaccination with a seasonal influenza vaccine.
We also found similar results after influenza vaccination in HIV-
infected patients.
The importance of anti-viral CD8 cells as well as recent
influenza pandemics (H5N1 and H1N1swine) have raised the need
of re-evaluating cellular responses [39–41]. Numerous reviews and
studies have highlighted the importance of respiratory virus-
specific effector and memory T cell responses in humans and mice
[41] that participate to the accelerated viral clearance as well as
enhanced survival after viral challenge [41–43]. In addition,
according to current concepts in HIV vaccine design, a broadly
targeting vaccine-specific CD8 response would restrict acute HIV
replication [44–47]. The HIV-infected population would consti-
tute one of the key populations that would benefit from such novel
vaccination strategies.
The aim of this approach is not yet to propose a vaccination
strategy for a seasonal influenza epidemic, but rather a proof-of-
concept study that the route of immunization will help in directing
immune responses towards a larger pool of CD8 responses against
infectious diseases. Conventional inactivated influenza vaccine was
used as an example for vaccination because of its ease to use and
wide acceptability by volunteers for clinical trials. The strength of
our work resides on the use of this type of vaccine, that has been
designed for antibody responses and not CD8 responses, rather the
use of live viruses.
Vaccines are classically injected into a muscle, where the local
deposit of vaccine compound must be captured by locally present
and recruited APCs. Muscles, however, have very few DCs, and
vaccines generally require adjuvant to improve their immunoge-
nicity. Because our method of vaccine application results in
opening the hair follicle, it should make skin DCs, including
epidermal LCs, which reside in and around the hair follicles,
highly accessible to topically applied vaccines [36,48]. Recent
studies suggest that DC subsets play a role in generating adaptive
immune responses of quantitatively and qualitatively distinct types
[49,50]. The elicitation of T cell responses by epicutaneous
immunization [34,51,52] suggests that LCs play a role. It was
recently shown that LCs cross-present exogenous antigen to CD8+
T cells in murine models [51,52]. Dermal DCs (in the dermis) and
LCs (in the epidermis) have different migratory paths through the
lymphoid tissues [53]. In addition, LCs generated in vitro and
derived from CD34+ precursors can cross-present exogenous
antigen to CD8+ cells [54] more potently than either dermal or
monocyte-derived DCs [55]. The efficacy of cellular immune
responses also appears to rely on strong antigen-induced priming
of T cells by efficient targeting and activation of professional APCs
[6,56].
In this study, vaccine was applied by a two-step protocol that
included a single CSSS procedure on the upper arm followed by
topical application of a total dose of a conventional influenza/
tetanus vaccine. The safety and tolerability of this CSSS procedure
in human volunteers was consistent with our previous findings in a
pilot study [37] of a limited number of healthy volunteers, where
we used CSSS and an anti-influenza vaccine (not combined with
any other product). Our first published pilot study was conducted
to define the surface area required for successful vaccination by
this method [37]. Previous studies have already demonstrated the
success of CSSS application in penetration of human skin [57,58].
This trial, however, is the first to demonstrate the safety of this
CSSS procedure in HIV-infected patients. Skin physiology
measurements confirmed that the skin parameters we measured
did not differ significantly between the two cohorts (healthy
volunteers and HIV-infected patients) or the two study arms (TC
versus IM administration). The TC vaccination protocol was also
safe in this specific patient population.
In recent years, various studies have recognized the feasibility of
TC vaccination in mice and even in humans (for review see [24]).
Safety and humoral responses to adjuvanted or live-inactivated
vaccines have been widely studied in humans, but not the
induction of cellular responses. In Phase I/II studies of a live-
attenuated measles vaccine in humans, Etchard et al. [59] recently
showed that TC – but not subcutaneous – immunization failed to
induce serum antibodies and induced only limited mucosal IgA
and IFN-c responses. Yagi and colleagues explored the induction
of T cell immune responses in five melanoma patients [60]. They
showed that five percutaneous immunizations (monthly applica-
tion of HIV and melanoma MHC-Class I restricted peptides)
allowed the induction of peptide-specific CD8 cells. In that study,
CSSS procedures led to complete removal of the stratum
corneum, on skin areas as large as 100 cm2. That study also used
substantially more than our single vaccine application; however,
we showed here that one application of influenza vaccine is
sufficient to induce cellular responses by the TC route. Further
dose-dependent vaccination needs to be performed in the future.
We previously explored the induction by TC and IM
vaccination of cellular immune responses in 11 healthy volunteers
(n = 6 TC and n= 4 IM) by a seasonal anti-influenza vaccine [37].
Interestingly, TC vaccination induced both CD4 and CD8 T cell
responses, whereas IM injection induced only effector CD4 T
cells. Nonetheless, the small sample size prevented effective
statistical analysis. The Phase I trial reported here showed a
significant difference according to route of administration in the
Figure 2. Flow cytometric representation of influenza-specific T cell response at day 28 post-vaccination by TC and IM routes. A, B)
Representative flow cytometric analysis of cytokine-producing influenza-specific effector CD4 and CD8 responses. Experiments were performed on
frozen PBMCs from individuals vaccinated by TC and IM routes as described in figure 1. Results are shown for a representative healthy individual with
a TC route (A) and an IM route (B) vaccination at day 28. C, D) Pie chart analyses of single (white), double (gray) and triple (black)-cytokine positive
cells for CD4 (C) and CD8 (D) effector cells specific for the indicated influenza protein. The expression of IFN-c, TNF-a, and/or IL-2
(triple+double+single cytokine positive cells) by influenza-specific T cells was analyzed with the Boolean gating function of FlowJo software. NA: not
applicable.
doi:10.1371/journal.pone.0010818.g002
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magnitude of the CD8 effector T cell population directed against
three distinct influenza vaccine proteins: hemagglutinins H3 and
H1 and NP. CD4 and CD8 cell response against the influenza
virus have been thoroughly described. It has been shown that CD8
cells make it possible to eliminate the virus [5,61–64] as well as to
control secondary infection by a lethal influenza strain in the
absence of B cells and antibodies [65,66]. CD8 cells specific for
influenza proteins may recognize viral epitopes such as nucleo-
protein (NP), polymerase acid (PA), matrix protein (M), and
nonstructural proteins [67–71]. In influenza infections in murine
models, protection by CD8 T cells has been shown to be derived
from restricting the dissemination of influenza A as well as of
influenza variants [72–76]. In elderly humans, cellular immune
responses against influenza correlated with protection against
influenza virus and thus indicated the limitations of using serum
antibody responses alone to measure vaccine efficacy [77,78].
Beyond the importance of CD8 immune responses in pandemic
influenza and vaccination in the elderly and other immunocom-
promised individuals, the magnitude of antigen-specific T cell
responses is a measure of vaccination efficacy against viral diseases
and also cancers. Efforts to improve vaccination efficacy will help
in the fight against these diseases. However, it does not reflect the
functional abilities that can be analyzed for an antigen-specific T
cell population. Currently flow cytometric techniques allow the
analysis of multiple functions. IFN-c, TNF, and IL-2 are analyzed
most often to assess cellular immunity to infectious diseases
[79,80]. It has been suggested that the quality of T cells is crucial
for determining the outcome of infectious diseases [10]. However,
quality is a critical point that has not yet been defined in terms of
control of viral diseases. Most reports of the multifunctionality of T
cells are based on studies of HIV infection or vaccination, and it
remains difficult to expand or generalize these results to other
infectious diseases or vaccinations. Combinations of markers can
paint a more detailed picture of antigen-specific T cells. We found
that the quality of polyfunctional CD8 and CD4 effector/memory
cells against influenza proteins (H3, H1, and NP) was similar at
baseline in both arms of the study and thus confirmed the relative
homogeneity of influenza-specific effector/memory cells before
vaccination. The TC and IM routes of vaccination that induced
differential cytokine profiles that suggested that the quality of CD4
cell stimulation by these routes might differ. The induction of CD8
responses after IM vaccination was extremely limited and did not
allow further analysis.
Nevertheless, vaccination by the TC route did not induce NAb
responses. This result may also be related in part to the strength of
immunization or the differential quality of the APCs, which can
dictate immunological outcome.
A major obstacle to skin vaccine delivery is the stratum
corneum, an important constituent of the skin barrier. Multiple
approaches have explored ways of overcoming it. Interestingly,
Fan et al. found that topical vaccination requires the presence of
intact hair follicles, which are the most relevant physiological
breaks in the skin barrier. They also highlighted the operation of
efficient mechanisms within the follicle for the induction of
immune responses against DNA vaccines [81]. Numerous studies
have recognized the importance of hair follicles in percutaneous
penetration processes [36,38,82,83]. The CSSS technique facili-
tates follicular penetration by removing cellular debris and sebum
from the hair follicle openings [82,83]. In contrast to previous
approaches, however, CSSS as it was used in this study had two
important effects on the skin. It removed approximately 30% of
the stratum corneum, inducing mild barrier disruption without
damaging the viable epidermis and its associated cell populations
(LCs), and it removed cellular debris from hair follicles, hereby
Figure 3. Differential induction of CD4 and CD8 T cell responses
after TC and IM vaccine application in HIV-infected volunteers.
Intracytoplasmic cytokine staining (ICS) of influenza-specific effector CD4
and CD8 responses was performed on frozen PBMCs from vaccinated
individuals. Experiments were performed on 12 HIV-infected individuals
for whom cell sample viability was at least 90% after thawing. Three
million cells were stimulated with the overlapping peptide covering H3,
H1, and NP for 12 hours at 37uC. Brefeldin A (5 mg/ml) was added 4 h
before harvesting. ICS was performed for IFN-c by flow-cytometric assay
on CD3+CD4+ (left panels) and CD3+CD8+ T cells (Right panels). At least
1,000,000 live events according to forward and side scatter parameters
were accumulated and analyzed (M&M section). The expression of IFN-c,
TNF-a, and/or IL-2 (triple+double+single cytokine positive cells) by
influenza-specific T cells was analyzed with the Boolean gating function
of FlowJo software. Results are shown as percentages of cytokine-
producing T cells (D Day 28-Day0) after subtracting the unstimulated cell
background. Mann-Whitney tests were used to compare continuous
variables between the groups. Significance was set at p,0.05.
doi:10.1371/journal.pone.0010818.g003
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increasing the number of hair follicles available for penetration.
This idea of utilizing the reservoir function of the hair follicle for
TC vaccination strategies is perfectly in line with recent reports by
Naito et al, who found that prolongation of antigen presence
increased the efficacy of TC immunization in mice [84]. While it
remains difficult to evaluate the amount of antigen to which the
immune system is actually exposed, this study supports the
experimental evidence from many studies that TC vaccination
may in fact allow dose sparing with equivalent T cell responses,
self-administration, and immune enhancement, even in elderly
patients with less responsive immune systems [85,86].
Materials and Methods
Study Design
The primary objective of this study was to evaluate the safety of
a newly developed protocol for TC vaccine application in healthy
volunteers (cohort I) and HIV-infected individuals (cohort II) by
using a commercially available tetanus/influenza vaccine (Teta-
gripH), in comparison to conventional IM injections. The
secondary objectives included first a comparison of the immuno-
genicity of TC and IM vaccination by assessing the tetanus- and
influenza-specific antibody titers and cellular immune responses,
and second, an evaluation of skin physiology in the patients in the
TC groups. The study included two cohorts of volunteers
composed of healthy individuals (cohort I, n = 24), and HIV-
infected patients (cohort II, n = 14), each randomized in two arms
i.e. TC versus IM vaccination, of 12 subjects per arm, as defined by
the Data Management and Statistics Center, according to an SAS
procedure plan. The volunteers were recruited at two investiga-
tional centers (Department of Dermatology and Allergy, Charite –
Universitaetsmedizin Berlin, Germany, and HIV Treatment &
Research Unit, Department of Internal Medicine II, Johann
Wolfgang Goethe University Hospital, Frankfurt, Germany). After
vaccination at D0, safety data were collected at D1, D3, D14,
D21, D28, and blood samples were taken for immunological
analyses at indicated time points (D0, D14 and D28). Skin
physiological measurements were performed before and after
vaccination at indicated time points. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information (Checklist S1, Flowchart S1 and Protocol S1).
Ethics committee approval, health authorities
The trial was conducted in accordance with the latest
Declaration of Helsinki, GCP, and ICH regulatory guidelines.
The study protocol, its first amendment, and the informed consent
and patient information forms were reviewed and approved by the
independent Ethics Committee of Charite – Universitaetsmedizin
Berlin, Campus Mitte, and submitted to the Ethics Committee of
Johann Goethe University, Frankfurt, Germany. Approval was
further obtained from the Paul-Ehrlich Institute, Germany
(Federal Agency of Sera and Vaccines). Written informed consent
was obtained from each volunteer before study entry. The clinical
trial has the following identification number NCT00261001.
Study population
Volunteers from both cohorts had to meet the following
eligibility criteria: men aged 18–45 years, body mass index
(BMI) 21–26, skin phototype I–IV, clinical examination and
interview for medical history, no tetanus vaccination within the
past four years, no influenza vaccination within the past year, no
psychological, familial, sociological or geographic condition that
might impede compliance with the study protocol, and written
informed consent. Men with excessive terminal hair growth on the
investigational sites were excluded from the study. Further
exclusion criteria were any acute or chronic illness, skin conditions
or allergies, or local or systemic treatments that might interfere
with the study protocol, and past or planned sessions of ultraviolet
or sun exposure within six weeks of study entry. Healthy
volunteers with a negative HIV test within three months of study
entry were included in cohort I. Inclusion in cohort II (HIV-
infected patients) required HIV-infection, positive HIV serology,
CD4 cell nadir .200/mm3, effective antiretroviral treatment with
a minimum of three drugs for ,1 year prior to study entry with a
plasma HIV RNA ,400cp/ml during the 6 months before the
inclusion and CD4+ counts .350 cells/mm3 for 12 months.
Vaccine
TETAGRIPH is a commercially available influenza/tetanus
vaccine (Sanofi-Pasteur, France). The vaccine is provided as
injectable suspension of one vaccine dose containing tetanus
anatoxin and inactivated influenza virus type A and type B
fragments of influenza antigens equivalent to 15 mg of 2 type-A (A/
CALIFORNIA/7/2004 H3N3 and A/NEW CALEDONIA/20/
99 H1N1) and 1 type-B (B/SHANGAI/361/2002) virus hemag-
glutinin subunits in saline solution. For TC and IM vaccination,
0.5 ml of the vaccine was used, as provided by the manufacturer.
TC and IM vaccination
TC vaccination was performed as described elsewhere, with a
newly developed standard operating procedure based on CSSS
[36,37]. Briefly, two investigational sites of 464 cm each were
delimited on the external part of the upper left arm with a
permanent skin marker (Skin marker H7003 Falc). The investi-
gational sites and the surrounding skin (2 cm on the top and
bottom of each investigational site and 1 cm on both sides) were
lightly shaved with a dry razor (Disposable razor, Art.-No. 182 H,
Wilkinson Sword GmbH, Germany). One CSSS was performed
with 190 mg cyanoacrylate (Superglue, UHU GmbH & Co. KG,
Germany), which was spread evenly on the skin surface with a
microscope slide. Adhesive tape (665 cm, Art.-No. 571176-
00000, Tesa Beiersdorf, Germany) was then applied and massaged
with a rubber roll to improve adhesion (10 times). After the glue
hardened for 20 minutes, tape and glue were removed from the
skin surface. A silicone barrier was placed to protect the area
around the investigational sites (Window-Colourpaste, Art.-
No. 4469/ko, Max-Bringmann GmbH & Co., Wendelstein,
Germany) to avoid spreading the vaccine. TETAGRIPH vaccine
(250 ml) was applied in droplets from the original syringe provided
by the manufacturer onto the skin surface of each investigational
site (16 drops per investigational site, each drop approximately
16 ml) and then gently massaged with gloved fingertip (care &
serveH) presaturated with vaccine for one minute. After an
incubation time of 20 minutes, a protective hydrocolloid bandage
(ComfeelH Plus Transparent 9614 cm Art.-Nr.: 3542, Coloplast
A/S, Denmark) was applied to the dried surface to protect the
investigational sites for 24 h. The volunteers were instructed not to
take a shower or bath and to avoid any activity that caused
sweating or mechanical stress to the investigational site, e.g.,
physical exercise, for these 24 hours.
For the IM group, TETAGRIPH vaccine (0.5 ml) as provided
by the manufacturer was injected intramuscularly into the deltoid
muscle of the left arm after careful disinfection, following the most
recent ICH Good Clinical Practices.
Clinical safety
After each immunization the volunteers remained under
medical supervision for at least 30 minutes. Safety data (local
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and systemic reactions, adverse events) were assessed and recorded
on D1, D3, D7, D14, D21, and D28. Each visit included an
interview, review of the diary cards, and a physical examination of
the volunteer. Local reactions were graded 0–3 (0 = none,
1 =mild, 2 =moderate, 3 = severe) according to the occurrence
of erythema, pruritus, burning, or desquamation. Systemic
reactions (e.g., rash, pain, fever, headache, shivering, diarrhea,
or malaise) were similarly graded 0–3. Severe adverse events were
graded 1–4 for each organ system according to clinical and
laboratory parameters defined in standard toxicity tables.
Skin physiology measurements
Transepidermal water loss (TEWL), stratum corneum hydra-
tion, skin pH, and sebum production were assessed before
vaccination on D0 with a Multi Probe Adapter MPAH (Courage-
Khazaka, Cologne, Germany). All skin measurements were
performed according to the manufacturer’s recommendation.
HAI titers
Serum antibody against influenza was measured at the Institut
Pasteur, the French national reference for influenza (Centre
National de Re´fe´rence de la Grippe) by a standard microtiter
hemagglutination inhibition (HAI) assay, as previously described
[87]. HAI antibody titers were determined before and after
influenza vaccination in all volunteers. Serum samples from D0,
D14, and D28 were simultaneously tested for strain-specific HAI
Results are reported for the A/CALIFORNIA/7/2004 strain.
The humoral response to this strain contained in the influenza
vaccine was assessed by calculating the geometric mean titers
before vaccination and at D14 and D28, and the fold increases in
the titer at D14 and D28.
Synthetic peptide design
Fifty-six overlapping 20-mer peptides covering the entire H1
hemagglutinin protein (strain A/NEW/CALEDONIA/20/99) –
included in European influenza vaccines over the past five years –
were synthesized (Altergen, France), and a super pool was
generated. Overlapping 20-mer peptides [88] (32 for H3 and 7
for nucleoprotein, NP) covering MHC Class I and II peptides of
the H3 hemagglutinin protein (strain A/CALIFORNIA/7/2004)
(not included in European influenza vaccines over the past five
years) and NP (strain A/NEW/CALEDONIA/20/99) were
designed based on epitopes described in the literature for 48 H3
and 44 NP peptides. To visualize the protein region rich in T cell
epitopes, sequences were aligned (MultalinH Software, INRA,
France) between the H3 hemagglutinin protein (strain A/
CALIFORNIA/7/2004) and all related T cell epitopes, thus
refining the 20-mer overlapping peptides. All peptides were
synthesized by Eurogentec, France.
Intracellular cytokine staining
Immunomonitoring studies were performed for the number of
individuals indicated below, that is, for the subjects whose frozen
blood samples were properly stored and had a cell viability
superior to 90% on thawing. All experiments were performed
blinded to study arm. Experiments were performed on frozen
PBMC samples from most subjects in both cohorts: i) in cohort I,
10/12 members of the TC group and 7 to 9/12 members of the
IM group and ii) in cohort II, 6/6 of the TC group and 6/8 of the
IM group. Frozen PBMCs were thawed in RPMI (Life
Technologies, France) containing 5% FCS (Seromed, Germany),
2 mmol/l L-glutamine (Gibco BRL, Life Technology, Scotland),
and antibiotics (1000 UI/ml penicillin sodium, 1 mg/ml strepto-
mycin sulfate, and 250 ng/ml amphotericin B). Cells were
stimulated with three different pools of 20-mer peptides (2 mg/
ml) for H1, H3, and NP antigens. Brefeldin A (5 mg/ml) (Sigma
Chemical Co., France) was added to the well four hours before
harvesting to detect intracellular cytokines. Then cells were stained
in PBS 16 for 10 min at RT, and membrane markers were added
for 20 min at 4uC. Next 100 ml of Fix and Perm Medium A
(Caltag, France) was added to each sample for 10 min at RT. Cells
were washed, resuspended with 100 ml of Fix and Perm Medium B
(Caltag, France), and incubated with intracellular monoclonal
antibodies (Abs) specific for cytokine detection for 20 min at RT.
The following panel of eight Abs was used: CD4-AmCyan, CD8-
PacificBlue, CD27-APC, CD45RA-ECD, IL2-FITC, IFN-c-
Alexa700, TNF-a-PE-C7. Flow cytometric analyses were done
with LSRII flow cytometers (Becton Dickinson, Immunocytometry
Systems). Analyses were performed with FlowJo software (Tree
Star). The live lymphocyte gate (at least 1,000,000 live events) was
set based on forward and side scatter for further analysis. The
expression of IFN-c, TNF-a, and IL-2 (triple+double+single
cytokine-positive cells) by influenza-specific T cells was analyzed
with the Boolean gating function of FlowJo software as described
previsouly [89,90,91]. Results are shown as percentages of
cytokine-producing T cells (D Day 28-Day 0) after subtracting
the background unstimulated cells. Responders are determined
when (D Day 28-Day 0) were superior to 0.
Statistical Analysis
The data analysis consisted of a comparison of safety and
immunogenicity data between study arms. All statistical analysis
was performed using SSPS 11 software or Prism 4.0c for Mac OS
X for data handling and graphic representation. The analysis
variables consisted of baselines variables, primary endpoints (safety
variables), and secondary endpoints (immunogenicity variables).
For baseline variables, descriptive analyses were performed (%,
median, interquartiles, ranges) by arm in each cohort. For safety
and immunogenicity the two arms were compared using non-
parametric tests: Fisher exact test for qualitative variables, Mann-
Whitney tests for continuous variables and x2-test for categorical
variables. Statistical significance was set at p,0.05.
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